GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS

Global and China Osteoporosis Drugs Market, Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates, Alderonate, Risedronate, Ibandronate, Zoledronic Acid, Others, Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor), Global and China Osteoporosis Drugs Market (By Route Of Adinistration: Oral, Injectable, Others), Global and China Osteoporosis Drugs Market (By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Sep 2023
Code : CMI4018
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global and China Osteoporosis Drugs Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global and China osteoporosis drugs market over the forecast period. This is due to the increasing number of drug discovey and drug development activities in the region. For instance, on April 27, 2023, a collaborative group of scientists from Florida International University- a U.S.-based public research university, hypothesized that increasing RXFP2 activity could increase bone formation in conditions like osteoporosis.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Gesrmany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
China
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa